Alunbrig

BRIGATINIB

Manufacturer: Takeda Pharmaceuticals America, Inc.

Score: 141.0

Quick Summary

Alunbrig (Brigatinib) is a kinase inhibitor used for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). The recommended dosage is 90 mg orally once daily for the first 7 days, then increased to 180 mg orally once daily. Important safety information includes warnings for interstitial lung disease (ILD)/pneumonitis, hypertension, bradycardia, visual disturbance, and creatine phosphokinase (CPK) elevation. There are no contraindications. Special population considerations include use during pregnancy, pediatric use, and geriatric use.

Key Clinical Findings and Indications

Treatment of adult patients with ALK-positive metastatic NSCLC
Efficacy in patients who have progressed on crizotinib
Improved progression-free survival and overall response rate compared to crizotinib

Important Safety Information

Warning

ILD/pneumonitis, hypertension, bradycardia, visual disturbance, and CPK elevation

Contraindications

Adverse Reactions

Diarrhea
Fatigue
Nausea
Rash
Cough
Myalgia
Headache
Hypertension
Vomiting
Dyspnea

Dosing Recommendations

General Guidance

Reduce dose for strong or moderate CYP3A inhibitors, increase dose for moderate CYP3A inducers

ALK-positive metastatic NSCLC

Adult Dose

90 mg orally once daily for the first 7 days, then increased to 180 mg orally once daily

Pediatric Dose

Not established

Special Population Considerations

Pregnancy

Can cause fetal harm
Advise pregnant women of potential risk

Nursing Mothers

Pediatric Use

Not established

Geriatric Use

No overall differences in safety or effectiveness observed between patients ≥65 years and younger patients

Similar Drugs

Lorbrena

LORLATINIB

Pfizer Laboratories Div Pfizer Inc

Similarity: 75.5%

Augtyro

REPOTRECTINIB

E.R. Squibb & Sons, L.L.C.

Similarity: 68.0%

Imbruvica

IBRUTINIB

Pharmacyclics LLC

Similarity: 64.3%

Dasatinib

DASATINIB

Apotex Corp.

Similarity: 62.9%

MEKTOVI

BINIMETINIB

Array BioPharma Inc.

Similarity: 62.2%